These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15208622)

  • 1. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Gokden M; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Br J Cancer; 2004 May; 90(9):1814-24. PubMed ID: 15208622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.
    Santin AD; Zhan F; Cane' S; Bellone S; Palmieri M; Thomas M; Burnett A; Roman JJ; Cannon MJ; Shaughnessy J; Pecorelli S
    Br J Cancer; 2005 Apr; 92(8):1561-73. PubMed ID: 15785748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Bandiera E; Rossi E; Donzelli C; Pasinetti B; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2007 Mar; 196(3):245.e1-11. PubMed ID: 17346539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
    Zhang Y; Garcia-Buitrago MT; Koru-Sengul T; Schuman S; Ganjei-Azar P
    Int J Gynecol Pathol; 2013 Sep; 32(5):476-81. PubMed ID: 23896709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
    El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
    Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
    Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.
    Cocco E; Bellone S; El-Sahwi K; Cargnelutti M; Casagrande F; Buza N; Tavassoli FA; Siegel ER; Visintin I; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2009 Jul; 101(2):335-41. PubMed ID: 19536090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
    Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
    Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
    Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
    Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
    Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD
    Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
    Macwhinnie N; Monaghan H
    Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
    Cocco E; Hu Z; Richter CE; Bellone S; Casagrande F; Bellone M; Todeschini P; Krikun G; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Lockwood CJ; Santin AD
    Br J Cancer; 2010 Sep; 103(6):812-9. PubMed ID: 20700124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
    Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
    J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.
    Cross SN; Cocco E; Bellone S; Anagnostou VK; Brower SL; Richter CE; Siegel ER; Schwartz PE; Rutherford TJ; Santin AD
    Am J Obstet Gynecol; 2010 Aug; 203(2):162.e1-8. PubMed ID: 20417484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.